Bugworks Research Inc. is a company headquartered in US with subsidiaries in India and Australia developing a novel class of antibiotics to tackle the problem of Antimicrobial Resistance (AMR)
Location: India, Karnataka, Bengaluru
Employees: 11-50
Total raised: $34.5M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Lightrock ... | lr-india.c... |
| 10.07.2026 | The Univer... | ut-ec.co.j... |
| - | Global Bra... | globalbrai... |
| 10.02.2022 | Lightrock | lightrock.... |
| 17.07.2021 | CARB-X | carb-x.org |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.04.2020 | Series B | $7.5M | - |
| 13.08.2018 | Series A | $9M | - |
| - | - | $18M | - |
Mentions in press and media 21
| Date | Title | Description |
| 17.04.2023 | Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark | BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoi... |
| 09.02.2022 | Bengaluru-based Biotech Startup Bugworks Research Has Raised USD 18 Mn In Its Series-B1 Round Led by Lightrock India | Bengaluru-based biotech startup Bugworks Research has announced a $18 Mn Series B1 round, which was led by Lightrock India, with participation from existing investors, including 3one4 Capital. The startup’s other investors include The Unive... |
| 09.02.2022 | Bugworks Research gets $18mn funding as it scales up clinical research | Bugworks Research, a therapeutics company, on Wednesday announced it got $18 million financing in a funding round. The Series B1 financing was led by Lightrock India and included existing investors the University of Tokyo Edge Capital (UTEC... |
| 09.02.2022 | Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India | This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, ... |
| 09.02.2022 | Therapeutics platform Bugworks Research snags $18 mn as Series B1 led by Lightrock India | Therapeutics company Bugworks Research on Wednesday said it has scooped up Series B1 funding of $18 million (around Rs 135 crore) led by Lightrock India. ADVERTISEMENT The round also saw participation from existing investors including The U... |
| 08.02.2022 | Bugworks Research bags $18 million in funding round led by Lightrock India, others | ETtech Chennai: Clinical stage multi-indication therapeutics company, Bugworks Research on Tuesday said it has bagged financing of $18 million in a Series B1 round that will support the clinical development of BWC0977, a novel broad spectru... |
| 08.11.2021 | Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections | BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-sp... |
| 18.05.2021 | UTEC, one of Asia’s largest deep-tech investment firms, launches new $275M fund | The University of Tokyo Edge Capital Partners (UTEC), a deep-tech investment firm, announced the first close of its fifth fund, which is expected to total 30 billion JPY (or about $275 million USD) by June 2021. UTEC currently has about $78... |
| 26.04.2021 | Bugworks secures funding from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats USA - English Deutschland - Deutsch Franc... | |
| 23.04.2020 | Bugworks raises $7.5 m from global investment syndicate | Bugworks Research Inc, a biopharma start-up that designs novel broad-spectrum antibiotics, has raised $7.5 million from a global investment syndicate to combat the challenge posed by deadly bacterial superbugs. The funding was led by Univer... |
Show more